(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine. Dhruv S. Kazi, M.D., from the University of California in San Francisco, and colleagues examined the effect of outcomes-based pricing on the cost-effectiveness of PCSK9